Immune checkpoints blockade can be a good way for cancer therapy because immune checkpoints act importantly in immunity to cancers. Thus it is significant to take advantages of blocking antibodies on the market to identify more checkpoint targets for cancer therapy.
PD1/PDCD1/CD279 is a T-cell surface protein, with inhibitory activaty when meeting with PD-L1/B7-H1/CD274. Some cancer cells can express increased PD-L1/B7-H1/CD274 to interact with PD1/PDCD1/CD279 and avoid immunity. So immune checkpoint blockade with PD1/PDCD1/CD279 and PD-L1/B7-H1/CD274 blocking antibodies can be a good way for cancer therapy.
|Blocking assay of PD1 antibodies||Blocking assay of PD-L1 antibodies|
|Fig. 1 Immune checkpoint blockage assay of PD1 / PDCD1 / CD279 Blocking Antibody (10377-mhT28).||Fig. 1 Immune checkpoint blockage assay of PD-L1 / B7-H1 / CD274 Blocking Antibody (10084-R639).|